A Single Vote Has Flipped Control Of Virginia's House Of Delegates


A recount in a Newport News district appears to have flipped the outcome and moved the House of Delegates to a 50-50 split between Republicans and Democrats, ending 17 years of GOP control.

This is the first time Republicans have not been in control of the Virginia House in almost two decades.

Even more stunning than the defeat is how Simonds won 11,608 votes while Yancey pulled up right behind her with 11,607.

"Christmas came early today for Virginia Democrats!" The recount still has to be certified by a three-judge panel, which will likely happen on Wednesday.

House Passes $1.5 Trillion GOP Tax Cut Bill
House Passes $1.5 Trillion GOP Tax Cut Bill

Democrat Shelly Simonds is the apparent victor in the race for the 94th District, beating incumbent Republican David Yancey.

Virginia Democrats have declared victory after victory in 2017. But after the votes were recounted late today, Democrat Shelly Simonds defeated Republican David Yancey by one vote, ending the GOP's 17-year majority.

But five hours and much nailbiting later, after painstaking counting overseen by local elections officials and the clerk of court, Yancey's lead narrowed before it gradually disappeared and then reversed, allowing Simonds to beat him by one vote. With the parties split 50-50, there is no mechanism to break ties and any legislation short of 51 votes does not advance. There is no tie-breaking mechanism in the Virginia House of Delegates, unlike the upper chamber in which the lieutenant governor can break ties. But an anti-Trump suburban wave helped transform a 66-34 Republican advantage into a deadlock, as well as delivering an eight-point victory for Democratic Ralph Northam in the governor's race. "I'm not approaching anybody.in the Senate or the House".

Jpmorgan Chase & Company Position In Pfizer INC (PFE) Was Has Boosted
Deutsche Bank set a $38.00 price target on Pfizer and gave the stock a "buy" rating in a research note on Wednesday, October 11th. Finally, UBS set a $38.00 price target on Pfizer and gave the company a "buy" rating in a report on Wednesday, November 1st.